NESS ZIONA, Israel, Feb. 8,
2018 /PRNewswire/ --BiondVax Pharmaceuticals Ltd.
(Nasdaq: BVXV), developer of a Universal Flu Vaccine candidate
currently in preparation for a Phase 3 clinical trial, and the
European UNISEC consortium announced today they will co-host
the Annual UNISEC Consortium Meeting, which will take place next
week in Jerusalem, Israel.
Attendees representing the consortium's partners from academia,
government, and industry will discuss achievements towards
development of a universal influenza vaccine, including the recent
successful results of the Phase 2b
clinical trial on BiondVax's universal flu vaccine candidate M-001.
Also expected to attend will be representatives from the U.S.
Department of Health and Human Services (HHS).
Dr. Ed Schmidt, Executive
Manager of the UNISEC consortium, commented, "UNISEC is
pleased to see the significant advancements we have enabled towards
improved influenza vaccines. We are grateful to the EU FP7 for
their financial support of UNISEC and previous consortia towards
this important goal. I also wish to thank the consortium partners
for their remarkable collaborative spirit and intensive work."
Dr. Ron Babecoff, BiondVax's CEO, noted, "The UNISEC
consortium collaboration has been a significant factor in
propelling BiondVax's universal flu vaccine towards our upcoming
pivotal Phase 3 trial. We are proud to be part of the UNISEC
consortium and honored to host this meeting in Jerusalem."
Babecoff continued, "Experts report that we are currently
experiencing the worst flu season since the 2009 pandemic. There is
wide consensus for the urgent need to develop a broadly protective
and effective influenza vaccine. BiondVax continues to lead the
global effort and hopes to be the first to bring to the world a
multi-strain multi-season universal flu vaccine, as our pivotal
clinical efficacy Phase 3 trial is starting later this year."
Research supporting UNISEC activities received funding from the
European Union Seventh Framework Programme (FP7/2007-2013) under
grant agreement n°602012.
About BiondVax Pharmaceuticals Ltd
BiondVax is an
advanced clinical stage biopharmaceutical company developing a
universal flu vaccine. The vaccine candidate, called M-001, is
designed to provide multi-season protection against current and
future, seasonal and pandemic influenza virus strains. BiondVax's
proprietary technology utilizes a unique combination of conserved
and common influenza virus peptides, activating both arms of the
immune system for a cross-protecting and long-lasting effect. In a
total of 6 completed Phase 1/2 and Phase 2 human clinical trials,
covering 698 participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. BiondVax is traded on NASDAQ:
BVXV. Please visit www.biondvax.com.
About UNISEC
Information regarding the UNISEC
Consortium is available at www.unisecconsortium.eu.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's
current views with respect to certain current and future events and
are subject to various risks, uncertainties and assumptions that
could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. risks and
uncertainties include, but are not limited to, the risk that drug
development involves a lengthy and expensive process with uncertain
outcome; the outcome of the Phase 3 trials; ability of the Company
to maintain, preserve and defend its intellectual property and
patents granted; whether our vaccine candidate will
successfully advance through the clinical trial process on a timely
basis, or at all, and receive approval from the United States
Food and Drug Administration or equivalent foreign regulatory
agencies; the adequacy of available cash resource and the ability
to raise capital when needed. More detailed information about
the risks and uncertainties affecting the Company is contained
under the heading "Risk Factors" in our Annual Report on Form 20-F
for the year ended December 31, 2016
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC's website, www.sec.gov, and in
the Company's periodic filings with the SEC and the Tel-Aviv Stock
Exchange.
For further information, please contact:
BiondVax
Joshua
Phillipson
+972-8-930-2529 x5105
j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/biondvax-and-european-unisec-consortium-to-host-universal-flu-vaccine-conference-300595742.html
SOURCE BiondVax Pharmaceuticals Ltd.